In patients with T2DM, elevated plasma levels of TGF- β1, CXCL-16 and angiopoietin-2 have been shown as independent predictors of albuminuria and these molecular markers can improve renal risk models beyond established clinical risk factors (Scurt et al., 2019). This evidence concerns the gene CXCL16 and type 2 diabetes mellitus.